Avadel Pharmaceuticals Reports First Quarter Earnings Miss of $0.13
May 11, 2023
Trending News 🌧️
Avadel Pharmaceuticals ($NASDAQ:AVDL), a specialty pharmaceutical company, released their first quarter earnings report that showed a miss of $0.13. The reported EPS came in at $-0.480 for the quarter compared to the estimated $-0.350. Revenue for the quarter was roughly in line with analyst estimates at $93.2M, essentially tracking the consensus of $93.1M. Avadel Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapeutics for the treatment of sleep and neurological disorders, pain relief and other disorders of unmet medical needs.
The company’s core therapeutic areas include narcolepsy, insomnia, restless leg syndrome, epilepsy and pain relief. The company has leveraged its expertise in drug development and regulatory affairs to develop an extensive portfolio of products. With its innovative product pipeline, Avadel is well-positioned to continue to meet the needs of patients worldwide.
Earnings
Compared to the year prior, the company has seen a net income loss of $30.78M USD and a total revenue decrease from $0.0M USD to $0.0M USD over the past three years. The company has yet to report any details on their latest financial results, but investors will be keeping a close eye on their performance going forward.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Avadel Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -141.82 | -103.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Avadel Pharmaceuticals. More…
| Operations | Investing | Financing |
| -66.49 | 42.51 | 46.98 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Avadel Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 140.74 | 178.91 | -0.59 |
Key Ratios Snapshot
Some of the financial key ratios for Avadel Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -49.5% | – | 35.4% |
| FCF Margin | ROE | ROA |
| -218.6% | 207.5% | -43.7% |
Price History
Despite the miss, the company’s stock saw an increase in price, opening at $14.2 and closing at $15.0, up 5.0% from its previous closing price. This increase in price could be attributed to the company’s continued progress and results in their new product launches and development, as well as other strategic initiatives. Additionally, investors are likely encouraged by the company’s strong cash position, which they have used to finance their operations and development efforts, as well as to pursue potential acquisitions. Despite the miss on earnings, Avadel Pharmaceuticals still looks poised to deliver strong financial results in the coming quarters. Live Quote…
Analysis
At GoodWhale, we conducted a thorough analysis of AVADEL PHARMACEUTICALS‘s fundamentals. We found that the company is classified as a high risk investment, according to its Risk Rating. An extensive review of the company’s financial statements, such as its income statement, balance sheet, cash flow statement, and financial journal revealed four risk warnings. We encourage potential investors to become a registered user of our platform to access more detailed information about AVADEL PHARMACEUTICALS’s risk warnings. With this comprehensive overview, you can make an informed decision about whether or not to invest in the company. As always, we are here to help you make sound, informed investments. More…
Peers
The company’s primary competitors are Mallinckrodt PLC, AcelRx Pharmaceuticals Inc, and Taro Pharmaceutical Industries Ltd.
– Mallinckrodt PLC ($NASDAQ:ACRX)
AcelRx Pharmaceuticals Inc is a pharmaceutical company that focuses on the development and commercialization of innovative therapies for the treatment of acute pain. The company’s lead product candidate, Dsuvia, is a 30 microgram sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain in medically supervised settings. AcelRx Pharmaceuticals Inc has a market cap of 20.41M as of 2022, a Return on Equity of -1155.51%. The company’s focus on developing innovative therapies for the treatment of acute pain makes it a promising investment for those looking to gain exposure to the healthcare sector.
– AcelRx Pharmaceuticals Inc ($NYSE:TARO)
Taro Pharmaceutical Industries Ltd is a pharmaceutical company with a market cap of 1.21B as of 2022. The company’s ROE is 1.92%. Taro Pharmaceutical Industries Ltd is engaged in the development, manufacture and marketing of generic pharmaceutical products. The company’s product portfolio includes finished dosage forms and active pharmaceutical ingredients. Taro Pharmaceutical Industries Ltd operates in two segments: Finished Dosage Forms and Active Pharmaceutical Ingredients. The Finished Dosage Forms segment includes oral solutions, ointments, creams, lotions, gels, capsules, tablets, powders and injectables. The Active Pharmaceutical Ingredients segment includes intermediates, bulk actives and formulations.
Summary
Avadel Pharmaceuticals recently reported first quarter earnings that were lower than expected, missing estimates by $0.13. Revenue was in line with expectations. Despite the miss, the company’s stock price rose on the same day. Analysts believe this could be due to the fact that the company’s sales growth and margins have both improved, and their product pipeline may hold potential for future growth.
The stock may also be supported by strong insider buying, as well as potential upside from new partnerships. Investors should monitor Avadel Pharmaceuticals closely for further developments.
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
